Ribometrix Inc.

Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific Officer https://lnkd.in/ezuPgQjR

At #ESMO24 we presented new preclinical data that support the potential of our small molecule eIF4E inhibitor, RBX-6610, as a potential treatment for non-small cell lung cancer (NSCLC) with KRAS, a common mutation. These data support RBX-6610’s anti-tumor activity both as a monotherapy and in combination, and in particular show its ability to re-sensitize KRASG12C NSCLC tumors with acquired resistance to standard-of-care treatment. This is a major potential addition to the standard-of-care as a majority of NSCLC tumors treated with the two approved KRAS inhibitor therapies develop resistance to these treatments. Read more about the new RBX-6610 data and the succession of tumor types in which we have demonstrated its potential at this link: https://lnkd.in/eVRy5EKj

Take a look at the latest exciting news from our amazing science team!

Today at #AACR24 we are presenting proof-of-concept data from our c-MYC program validating our #RNA-targeting platform’s ability to directly target RNA with a small molecule and reduce associated protein levels, a longtime goal of RNA therapeutic development. We are also presenting data supporting our RNA-binding protein inhibitor program targeting eIF4E as a potential anti-cancer therapy.?https://lnkd.in/ecyAYEd7

We’re excited to share that we’ll be at ESMO - European Society for Medical Oncology Congress in Barcelona from September 13-17, sharing the latest data from our eIF4E program. We continue to see promising data supporting the potential of eIF4e inhibition in multiple tumor types, including a common type of non-small cell lung cancer (NSCLC). In the U.S. alone, tens of thousands of people are diagnosed with this cancer every year, and, for many, initially promising responses to approved therapies do not last because their tumors acquire resistance. Our data show the potential for our approach to restore the sensitivity of tumors to standard of care, as we have now shown in lung, breast, colon and skin cancer. ? Our full presentation and data will be shared on September 15, 2024, when our colleague Dr. Andrew Truong represents our team and presents the poster at the conference.

We’re excited to share that we’ll be at ESMO - European Society for Medical Oncology Congress in Barcelona from September 13-17, sharing the latest data from our eIF4E program. We continue to see promising data supporting the potential of eIF4e inhibition in multiple tumor types, including a common type of non-small cell lung cancer (NSCLC). In the U.S. alone, tens of thousands of people are diagnosed with this cancer every year, and, for many, initially promising responses to approved therapies do not last because their tumors acquire resistance. Our data show the potential for our approach to restore the sensitivity of tumors to standard of care, as we have now shown in lung, breast, colon and skin cancer. ? Our full presentation and data will be shared on September 15, 2024, when our colleague Dr. Andrew Truong represents our team and presents the poster at the conference.

Today at #AACR24 we are presenting proof-of-concept data from our c-MYC program validating our #RNA-targeting platform’s ability to directly target RNA with a small molecule and reduce associated protein levels, a longtime goal of RNA therapeutic development. We are also presenting data supporting our RNA-binding protein inhibitor program targeting eIF4E as a potential anti-cancer therapy.?https://lnkd.in/ecyAYEd7

Today at #AACR24 we are presenting proof-of-concept data from our c-MYC program validating our #RNA-targeting platform’s ability to directly target RNA with a small molecule and reduce associated protein levels, a longtime goal of RNA therapeutic development. We are also presenting data supporting our RNA-binding protein inhibitor program targeting eIF4E as a potential anti-cancer therapy.?https://lnkd.in/ecyAYEd7

We’re proud to announce that Ribometrix is sharing new preclinical data at the 2024 #AACR Annual Meeting for our pioneering #RNA-modulating small molecule programs targeting elF4E and c-MYC. The data support our ability to employ multiple RNA-modulating strategies to address well-validated, but difficult-to-drug therapeutic targets, including in cancers with high unmet need. We’re thrilled to advance novel solutions for challenging diseases. Read more about our progress and upcoming AACR data:?https://lnkd.in/eCGEuVry

We’re proud to announce that Ribometrix is sharing new preclinical data at the 2024 #AACR Annual Meeting for our pioneering #RNA-modulating small molecule programs targeting elF4E and c-MYC. The data support our ability to employ multiple RNA-modulating strategies to address well-validated, but difficult-to-drug therapeutic targets, including in cancers with high unmet need. We’re thrilled to advance novel solutions for challenging diseases. Read more about our progress and upcoming AACR data:?https://lnkd.in/eCGEuVry